Products for Research Use Only
RegisterLogin

Ki20227

CAT: 0804-HY-10408-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10408-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β) . Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction[1].
CAS Number
623142-96-1
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
C-Fms; c-Kit; PDGFR; VEGFR
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Ki20227.html
Concentration
10mM
Purity
99.51
Solubility
DMSO : 62.5 mg/mL (ultrasonic)
Smiles
O=C(NC1=CC=C(C=C1OC)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC(C)C4=NC=CS4
Molecular Formula
C24H24N4O5S
Molecular Weight
480.54
Precautions
H302, H315, H319, H335
References & Citations
[1]Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5 (11) :2634-43.|[2]Boru Hou, et al. Ki20227 influences the morphology of microglia and neurons through inhibition of CSF1R during global ischemia. Int J Clin Exp Pathol. 2016;9 (12) :12459-12469.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Alternative Products

CatalogName
GW9361-1mgKi20227

Popular Products